PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Erdosteine→

Erdosteine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
84611-23-4
Molecular formula
C8H11NO4S2
Molecular weight
249.299 g/mol
Drug class
Mucolyticprodrug with thiol-containing active metabolite
Mechanism of action
Erdosteine is a prodrug. First-pass metabolism releases free thiol groups that open disulphide bonds in bronchial mucoproteins, reducing mucus viscosity. The active metabolite also has antioxidant activity and can inhibit bacterial adhesion to epithelial cells.
Indications / reported uses
  • Expectorant and symptomatic treatment of acute exacerbations of chronic bronchitis in adults under the cited UK SmPC; other national product information may include additional acute/chronic respiratory conditions with excessive mucus

Sources: UK SmPC — Erdotin 300 mg capsules · Singapore National Drug Formulary — Erdomed · Malaysia NPRA Technical Evaluation Summary · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Erdosteine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Erdosteine Permitted Daily Exposure (PDE) report (the Erdosteine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Erdosteine Occupational Exposure Limit (OEL) report (the Erdosteine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.